No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Alprolix is a recombinant Factor IX (FIX) therapy used to treat and prevent bleeding episodes in adults and children with hemophilia B. It is a genetically engineered version of the naturally occurring human FIX protein, which is missing or deficient in people with hemophilia B. Alprolix is administered as a subcutaneous injection and works by replacing the missing FIX protein, allowing the blood to clot normally.
The Alprolix market is a subset of the larger hematological drugs market, which includes treatments for a variety of blood-related disorders. Hematological drugs are used to treat conditions such as anemia, leukemia, and lymphoma, as well as hemophilia. Alprolix is the only recombinant FIX therapy approved for use in the United States.
Some companies in the Alprolix market include Biogen, Bayer, and Novo Nordisk. Biogen is the manufacturer of Alprolix, while Bayer and Novo Nordisk both produce other treatments for hemophilia B. Show Less Read more
